

Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-09-04 | 149 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$3999.00
- Five User Licence \$4999.00
- Enterprisewide License \$5999.00

Report description:

Market Overview:

The global cancer vaccines market size reached US\$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 12.1 Billion by 2028, exhibiting a growth rate (CAGR) of 11.61% during 2023-2028.

Cancer is a malignant tumor caused by the uncontrollable growth of abnormal cells in the body. It can be treated through the use of various medications and vaccines. Between these, vaccines are broadly categorized into preventive and therapeutic. Preventive cancer vaccines are deployed for eliminating cancer caused by oncovirus and protecting from human papillomavirus (HPV), whereas therapeutic vaccines aid in stimulating the individual adaptive immune systems by using tumor antigens. At present, cancer vaccines are commercially available in varying types, such as antigen, dendritic cell, and anti-idiotypic.

Cancer Vaccines Market Trends:

The increasing prevalence of cancer, especially due to the rising consumption of tobacco-based products and evolving lifestyles is currently driving the cancer vaccines market growth. In line with this, favorable initiatives undertaken by the government bodies of several nations for introducing novel cancer vaccines, along with extensive fundings in the field of viral recombinant cancer vaccines are further facilitating the widespread adoption of these vaccines in the healthcare sector. In line with this, the extensive utilization of United States Food and Drug Administration (US FDA) approved vaccines, including human papillomavirus vaccine (HPV) and hepatitis B vaccine (HBV) to reduce the risk of certain types of cancer, such as liver cancer, is contributing to the market growth. The market is also significantly driven by rapid technological advancements focusing on the development of effective and specific cancer treatments. Other factors, such as improving healthcare infrastructure, rising geriatric population, who are susceptible to various chronic ailments, including cancer, and growing consumer awareness regarding the symptoms and the available treatment options, are creating a positive outlook for the market further across the globe.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer vaccines market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, technology, indication and end user.

Breakup by Type:

Preventive Cancer Vaccines
Therapeutic Cancer Vaccines

Breakup by Technology:

Dendritic Cells Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Whole-cell Cancer Vaccines

Breakup by Indication:

Cervical Cancer
Prostate Cancer
Others

Breakup by End User:

Pediatrics
Adults

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.

Key Questions Answered in This Report:

How has the global cancer vaccines market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global cancer vaccines market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global cancer vaccines market and who are the key players?
What is the degree of competition in the industry?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
 - 2.1 Objectives of the Study
 - 2.2 Stakeholders
 - 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
 - 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
 - 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
 - 4.1 Overview
 - 4.2 Key Industry Trends
- 5 Global Cancer Vaccines Market
 - 5.1 Market Overview
 - 5.2 Market Performance
 - 5.3 Impact of COVID-19

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.4 Market Forecast
- 6 Market Breakup by Type
 - 6.1 Preventive Cancer Vaccines
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
 - 6.2 Therapeutic Cancer Vaccines
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 7 Market Breakup by Technology
 - 7.1 Dendritic Cells Cancer Vaccines
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
 - 7.2 Recombinant Cancer Vaccines
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
 - 7.3 Antigen/Adjuvant Cancer Vaccines
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast
 - 7.4 Viral Vector and DNA Cancer Vaccines
 - 7.4.1 Market Trends
 - 7.4.2 Market Forecast
 - 7.5 Whole-cell Cancer Vaccines
 - 7.5.1 Market Trends
 - 7.5.2 Market Forecast
- 8 Market Breakup by Indication
 - 8.1 Cervical Cancer
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
 - 8.2 Prostate Cancer
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
 - 8.3 Others
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast
- 9 Market Breakup by End User
 - 9.1 Pediatrics
 - 9.1.1 Market Trends
 - 9.1.2 Market Forecast
 - 9.2 Adults
 - 9.2.1 Market Trends
 - 9.2.2 Market Forecast
- 10 Market Breakup by Region
 - 10.1 North America
 - 10.1.1 United States
 - 10.1.1.1 Market Trends
 - 10.1.1.2 Market Forecast
 - 10.1.2 Canada

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
 - 10.2.1 China
 - 10.2.1.1 Market Trends
 - 10.2.1.2 Market Forecast
 - 10.2.2 Japan
 - 10.2.2.1 Market Trends
 - 10.2.2.2 Market Forecast
 - 10.2.3 India
 - 10.2.3.1 Market Trends
 - 10.2.3.2 Market Forecast
 - 10.2.4 South Korea
 - 10.2.4.1 Market Trends
 - 10.2.4.2 Market Forecast
 - 10.2.5 Australia
 - 10.2.5.1 Market Trends
 - 10.2.5.2 Market Forecast
 - 10.2.6 Indonesia
 - 10.2.6.1 Market Trends
 - 10.2.6.2 Market Forecast
 - 10.2.7 Others
 - 10.2.7.1 Market Trends
 - 10.2.7.2 Market Forecast
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.1.1 Market Trends
 - 10.3.1.2 Market Forecast
 - 10.3.2 France
 - 10.3.2.1 Market Trends
 - 10.3.2.2 Market Forecast
 - 10.3.3 United Kingdom
 - 10.3.3.1 Market Trends
 - 10.3.3.2 Market Forecast
 - 10.3.4 Italy
 - 10.3.4.1 Market Trends
 - 10.3.4.2 Market Forecast
 - 10.3.5 Spain
 - 10.3.5.1 Market Trends
 - 10.3.5.2 Market Forecast
 - 10.3.6 Russia
 - 10.3.6.1 Market Trends
 - 10.3.6.2 Market Forecast
 - 10.3.7 Others
 - 10.3.7.1 Market Trends
 - 10.3.7.2 Market Forecast
- 10.4 Latin America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4.1 Brazil
 - 10.4.1.1 Market Trends
 - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
 - 10.4.2.1 Market Trends
 - 10.4.2.2 Market Forecast
- 10.4.3 Others
 - 10.4.3.1 Market Trends
 - 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
 - 10.5.1 Market Trends
 - 10.5.2 Market Breakup by Country
 - 10.5.3 Market Forecast
- 11 SWOT Analysis
 - 11.1 Overview
 - 11.2 Strengths
 - 11.3 Weaknesses
 - 11.4 Opportunities
 - 11.5 Threats
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
 - 13.1 Overview
 - 13.2 Bargaining Power of Buyers
 - 13.3 Bargaining Power of Suppliers
 - 13.4 Degree of Competition
 - 13.5 Threat of New Entrants
 - 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
 - 15.1 Market Structure
 - 15.2 Key Players
 - 15.3 Profiles of Key Players
 - 15.3.1 Anixa Biosciences Inc.
 - 15.3.1.1 Company Overview
 - 15.3.1.2 Product Portfolio
 - 15.3.1.3 Financials
 - 15.3.2 Dendreon Pharmaceuticals LLC
 - 15.3.2.1 Company Overview
 - 15.3.2.2 Product Portfolio
 - 15.3.3 Dynavax Technologies Corporation
 - 15.3.3.1 Company Overview
 - 15.3.3.2 Product Portfolio
 - 15.3.3.3 Financials
 - 15.3.4 GSK plc
 - 15.3.4.1 Company Overview
 - 15.3.4.2 Product Portfolio
 - 15.3.4.3 Financials

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.4.4 SWOT Analysis
- 15.3.5 Merck & Co. Inc.
 - 15.3.5.1 Company Overview
 - 15.3.5.2 Product Portfolio
 - 15.3.5.3 Financials
 - 15.3.5.4 SWOT Analysis
- 15.3.6 Moderna Inc.
 - 15.3.6.1 Company Overview
 - 15.3.6.2 Product Portfolio
 - 15.3.6.3 Financials
- 15.3.7 OSE Immunotherapeutics
 - 15.3.7.1 Company Overview
 - 15.3.7.2 Product Portfolio
 - 15.3.7.3 Financials
- 15.3.8 Providence Therapeutics
 - 15.3.8.1 Company Overview
 - 15.3.8.2 Product Portfolio
- 15.3.9 Sanofi S.A.
 - 15.3.9.1 Company Overview
 - 15.3.9.2 Product Portfolio
 - 15.3.9.3 Financials
 - 15.3.9.4 SWOT Analysis
- 15.3.10 UbiVac Inc.
 - 15.3.10.1 Company Overview
 - 15.3.10.2 Product Portfolio
- 15.3.11 Vaccitech plc
 - 15.3.11.1 Company Overview
 - 15.3.11.2 Product Portfolio
 - 15.3.11.3 Financials

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-09-04 | 149 pages | IMARC Group

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
<input type="checkbox"/>	Electronic (PDF) Single User	\$3999.00
<input type="checkbox"/>	Five User Licence	\$4999.00
<input type="checkbox"/>	Enterprisewide License	\$5999.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

